Eloralintide for Obesity

(ENLIGHTEN-6 Trial)

This trial tests eloralintide, a treatment for individuals with persistent obesity or who are overweight, to determine its effectiveness in weight loss and safety. Participants will receive one of four doses of eloralintide or a placebo (a substance with no active drug) to compare outcomes. The trial suits those on stable incretin therapy who struggle with obesity or being overweight, particularly if they also face high blood pressure, sleep apnea, or type 2 diabetes. Participants must have a stable body weight and meet specific health criteria to qualify. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

The trial requires participants to be on stable incretin therapy, so you won't need to stop that medication. However, if you're taking certain diabetes medications like DPP-4 inhibitors, amylin analogs, or insulin, you must stop them at least 90 days before joining the trial.

Research shows that eloralintide, a treatment under study for obesity, has shown promise in earlier studies. One study found that participants lost a significant amount of weight, between 9.5% and 20.1%, over 48 weeks. Importantly, most participants did not experience severe side effects, indicating it was generally well-tolerated.

Other research also supports the safety of eloralintide. It has been tested in individuals who are overweight or have obesity, and results suggest it is safe for humans. These studies indicate that eloralintide is usually well-tolerated, with side effects being mild to moderate.

Eloralintide is unique because it offers a fresh approach to tackling obesity by being administered subcutaneously, which could potentially improve patient compliance compared to oral medications. Most existing treatments for obesity, like orlistat or liraglutide, either reduce fat absorption or mimic hormones that regulate appetite and glucose. Eloralintide, on the other hand, may target different pathways to influence weight regulation, although its exact mechanism is still being explored. Researchers are particularly excited about Eloralintide because it might offer an alternative for those who haven't seen success with current methods, providing a new option in the fight against obesity.

Research has shown that eloralintide can aid weight loss in people with obesity. In studies, participants taking eloralintide lost between 9.5% and 20.1% of their body weight over 48 weeks. The weight loss varied with the dose, with higher doses resulting in greater weight loss. In this trial, participants will receive different doses of eloralintide to assess its effectiveness and safety. Eloralintide controls appetite, aiding in weight management. Most participants tolerated it well, experiencing no serious side effects. These findings suggest that eloralintide could effectively manage obesity.²⁴⁵⁶⁷